Invokana Tablet, Film Coated
NDC Package 55154-1425-8
Package Information
Invokana (canagliflozin) tablets is canagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. This formulation utilizes a tablet, film coated delivery system. Marketed by Cardinal Health 107, Llc, this product is identified by NDC 55154-1425 and is authorized under FDA application NDA204042.
Identification & Billing
- RxCUI: 1373463 - canagliflozin 100 MG Oral Tablet
- RxCUI: 1373463 - canagliflozin (as canagliflozin hemihydrate) 100 MG Oral Tablet
- RxCUI: 1373469 - Invokana 100 MG Oral Tablet
- RxCUI: 1373469 - canagliflozin 100 MG Oral Tablet [Invokana]
- RxCUI: 1373471 - canagliflozin 300 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 55154 - Cardinal Health 107, Llc
- 55154-1425 - Invokana
- 55154-1425-8 - 2070 TABLET, FILM COATED in 1 BOTTLE
- 55154-1425 - Invokana
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55154-1425-8 identifies a specific commercial package of 2070 tablet, film coated in 1 bottle of Invokana, a human prescription drug labeled by Cardinal Health 107, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 2070 billable units per package. This tablet, film coated is formulated for oral use and contains canagliflozin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cardinal Health 107, Llc on March 29, 2013. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Canagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Canagliflozin is also used by people with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke. Canagliflozin is also used by people with type 2 diabetes and kidney disease to lower the risk of dialysis, death from heart disease, and the need to go to the hospital for heart failure. Canagliflozin works by increasing the removal of sugar by your kidneys.
How is this Cardinal Health 107, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55154142508. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 2070 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.